Ask HopeStage to review this study with me
Study ID: NCT04738123. We help you review the study, but cannot decide medical eligibility.
CompletedNCT04738123
KarXT for schizophrenia
This study is completed in the United States and in Ukraine. It is testing KarXT for schizophrenia.
SchizophreniaDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Ukraine · 12 sites
- Dnipropetrovsk Regional Clinical Hospital named after I.I. MechnikovDniproSite status: Not listed — confirm with the team
- Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of UkraineKharkivSite status: Not listed — confirm with the team
- Regional Clinical Psychiatric Hospital No. 3, Adult Psychiatric Department No. 3KharkivSite status: Not listed — confirm with the team
- Regional Clinical Psychiatric Hospital No. 3, Psychiatric Department for First Episode PsychosisKharkivSite status: Not listed — confirm with the team
- Kherson Regional Institution of Mental CareKhersonSite status: Not listed — confirm with the team
- Kyiv City Psychoneurological Hospital #2KyivSite status: Not listed — confirm with the team
- Kyiv Regional Medical Incorporation "Psychiatry", Center for Novel Treatment and Rehabilitation of Psychotic DisordersKyivSite status: Not listed — confirm with the team
- Lviv Regional Clinical Psychiatric Hospital, Department #20LvivSite status: Not listed — confirm with the team
- Lviv Regional Clinical Psychiatric Hospital, Department #25LvivSite status: Not listed — confirm with the team
- Regional Institution of Mental Psychiatric Care of the Poltava Regional CouncilPoltavaSite status: Not listed — confirm with the team
- Cherkasy Regional Psychiatric Hospital of Cherkasy Regional CouncilSmilaSite status: Not listed — confirm with the team
- M.I. Pyrogov Vinnytsya National Medical UniversityVinnytsiaSite status: Not listed — confirm with the team
United States · 20 sites
- Pillar Clinical ResearchBentonville, ArkansasSite status: Not listed — confirm with the team
- Woodland International Research GroupLittle Rock, ArkansasSite status: Not listed — confirm with the team
- Advanced Research Center, Inc.Anaheim, CaliforniaSite status: Not listed — confirm with the team
- Clinical Innovations, IncBellflower, CaliforniaSite status: Not listed — confirm with the team
- ProScience Research GroupCulver City, CaliforniaSite status: Not listed — confirm with the team
- Collaborative Neuroscience Research, LLC.Garden Grove, CaliforniaSite status: Not listed — confirm with the team
- CNS NetworkLong Beach, CaliforniaSite status: Not listed — confirm with the team
- NRC Research InstituteOrange, CaliforniaSite status: Not listed — confirm with the team
- Artemis Institute for Clinical ResearchSan Diego, CaliforniaSite status: Not listed — confirm with the team
- Behavioral Clinical Research, Inc.Hollywood, FloridaSite status: Not listed — confirm with the team
- Larkin Behavioral Health ServicesHollywood, FloridaSite status: Not listed — confirm with the team
- Atlanta Center for Medical ResearchAtlanta, GeorgiaSite status: Not listed — confirm with the team
- iResearch Atlanta, LLCDecatur, GeorgiaSite status: Not listed — confirm with the team
- AMITA Health Center for Psychiatric ResearchChicago, IllinoisSite status: Not listed — confirm with the team
- Uptown Research InstituteChicago, IllinoisSite status: Not listed — confirm with the team
- AMITA Health Center for Psychiatric ResearchHoffman Estates, IllinoisSite status: Not listed — confirm with the team
- Hassman Research InstituteBerlin, New JerseySite status: Not listed — confirm with the team
- Hassman Research InstituteMarlton, New JerseySite status: Not listed — confirm with the team
- Community Clinical Research, Inc.Austin, TexasSite status: Not listed — confirm with the team
- InSite Clinical Research, LLCDeSoto, TexasSite status: Not listed — confirm with the team
Key information made simple
What is this study testing?
This study is testing whether KarXT may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive KarXT, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Ukraine and in the United States.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Study sites are listed in the registry. Recruitment status can differ between sites. Ask the research team to confirm the location, any in-person visits, time commitment, costs or compensation, and participation criteria.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: April 6, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 256
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Ukraine
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04738123
- Official title
- A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 Schizophrenia
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT04738123. We help you review the study, but cannot decide medical eligibility.
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Xanomeline and Trospium Chloride Capsules, Placebo. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company, which appears to be a biotech company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT01157351
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
This study is completed. It focuses on schizophrenia and currently lists study information in the United States.
CompletedNCT01714713
EVP-6124 (Alpha-7 nAChR) for schizophrenia
This study is completed in the United States, in Australia, in Canada, .... It is testing EVP-6124 (Alpha-7 nAChR) for schizophrenia.
CompletedEUCTR 2013-001695-38
A 6-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENT SUBJECTS WITH SCHIZOPHRENIA
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.